Keratoacanthoma - Keratoakantom
☆ U rezultatima Stiftung Warentest iz Njemačke za 2022., zadovoljstvo potrošača s ModelDermom bilo je samo malo niže nego s plaćenim konzultacijama o telemedicini.
Tipično Keratoakantom (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) je čest tumor kože poznat po brzom rastu i mogućnosti da se sam povuče. Obično se javlja kod starijih muškaraca svijetle puti s poviješću izlaganja suncu. Iako je kirurško uklanjanje ekscizijom ili Mohsove mikrografske kirurgije uobičajeno liječenje, postoje i druge terapijske mogućnosti.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) je tumor niskog stupnja koji nastaje u određenim žlijezdama kože i pod mikroskopom izgleda slično squamous cell carcinoma (SCC). U tijeku je rasprava o tome treba li KA klasificirati kao oblik invazivnog SCC‑a.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) je druga najčešća vrsta raka kod ljudi, posebno među starijim osobama. Kirurški zahvat obično se koristi za liječenje cSCC‑a, ali za neke pacijente koji ne mogu podvrgnuti se operaciji ili je ne žele, mogu se razmotriti druge mogućnosti, poput intralezijske terapije. Tradicionalni intralezijski tretmani (methotrexate or 5-fluorouracil) su korišteni, ali u tijeku su istraživanja novih pristupa, poput intralezijske imunoterapije i onkolitičke viroterapije. Ovdje ćemo pregledati različite intralezijske tretmane za cSCC, od klasičnih metoda do najsuvremenijih strategija.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Pod mikroskopom keratoakantom (keratoacanthoma) vrlo nalikuje karcinomu skvamoznih stanica. Dok neki patolozi klasificiraju keratoakantom (keratoacanthoma) kao poseban entitet, a ne kao zloćudnu bolest, oko 6 % kliničkih i histoloških slučajeva keratoakantom (keratoacanthoma) napreduje u invazivne i agresivne karcinome skvamoznih stanica.
○ Dijagnostika i liječenje
#Dermoscopy
#Skin biopsy